# Patch Biosciences

> Patch Biosciences developed programmable DNA medicines before the biotech wound down or was acquired.

## Why it is interesting

A synthetic-biology play in the a16z bio portfolio targeting programmable therapeutics — early-stage platform for gene-level drug design.

## Profile

- **Stage:** acquired
- **Status:** acquired
- **Industries:** generalist-tech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- a16z portfolio status: Exit
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/patch-biosciences